Design of Industrial Cold-Formed Steel Rack Upright Frames for Loads in Cross-Aisle Direction

This paper summarizes research on the cross-aisle stiffness and strength of industrial cold-formed steel rack upright frames for loads in cross-aisle direction. Tests were carried out at the Universitat Politècnica de Catalunya, Barcelona, Spain on joints as well as entire upright frames. A possible rather simple analysis procedure is developed and described

Industrial Cold-Formed Steel Rack Column Base Fixity and Strength

This paper summarizes the testing done at the Universitat Politècnica de Catalunya, Barcelona, Spain and the possible use of the results in design for column base stiffness and strength. The test setup and procedure are adopted in the European rack design standards

Conèixer les variants genètiques individuals per personalitzar el tractament contra la Leucèmia Infantil

La individualització del tractament de la Leucèmia Limfoblàstica Aguda és clau per millorar la supervivència dels pacients amb aquesta malaltia, la qual representa un terç de tots els càncers infantils. En aquest estudi es van analitzar uns gens involucrats en la mort de les cèl·lules canceroses i es va trobar una associació entre la presència d'unes variants genètiques en aquests gens i la supervivència dels pacients. Si aquests resultats es confirmen en una sèrie més àmplia de pacients, es podrien identificar aquells individus amb un alt risc de resistència als agents quimioteràpics basats en la mort cel·lular programada (apoptosi), de manera que podrien ser tractats amb altres teràpies més agressives.La individualización del tratamiento de la Leucemia Linfoblástica Aguda es clave para mejorar la supervivencia de los pacientes con esta enfermedad, la cual representa un tercio de todos los cánceres infantiles. En este estudio se analizaron unos genes involucrados en la muerte de las células cancerosas y se encontró una asociación entre la presencia de unas variantes genéticas en estos genes y la supervivencia de los pacientes. Si estos resultados se confirman en una serie más amplia de pacientes, se podrían identificar aquellos individuos con un alto riesgo de resistencia a los agentes quimioterápicos basados en la muerte celular programada (apoptosis), por lo que podrían ser tratados con otras terapias más agresivas.Individualization of treatment for Acute Lymphoblastic Leukemia is key to improving survival for patients with this disease, which accounts for one third of all childhood cancers. This study analyzed genes involved in the death of cancer cells, and found an association between the presence of genetic variants in these genes and the survival of patients. If these results are confirmed in a broader series of patients, those individuals at high risk for resistance to chemotherapy agents based on programmed cell death (apoptosis) could be identified, so they could be treated with other, more aggressive therapies

Possible implicació dels gens MDM2 i TP53 en el risc a desenvolupar neoplàsies mieloides secundàries

En els últims anys, la incidència de càncers secundaris a la teràpia (desenvolupament d'un altre càncer després de superar el primer) ha augmentat considerablement. Aquest fet suposa un problema greu ja que moltes vegades no responen als tractaments convencionals i tenen una pitjor evolució. Per tant, comprendre'n el seu origen, risc i funcionament és clau per futurs diagnòstics i tractaments. En aquest article, s'ha investigat si les variants genètiques dels gens MDM2 i TP53, implicats en la via p53, poden estar associades amb la susceptibilitat a les neoplàsies mieloides (càncers secundaris més freqüents) relacionades amb la teràpia.En los últimos años, la incidencia de cánceres secundarios a la terapia (desarrollo de otro cáncer tras superar el primero) ha aumentado considerablemente. Este hecho supone un problema grave ya que muchas veces no responden a los tratamientos convencionales y tienen una peor evolución. Por lo tanto, comprender su origen, riesgo y funcionamiento es clave para futuros diagnósticos y tratamientos. En este artículo, se ha investigado si las variantes genéticas de los genes MDM2 y TP53, implicados en la vía p53, pueden estar asociadas con la susceptibilidad a las neoplasias mieloides (cánceres secundarios más frecuentes) relacionadas con la terapia.Over the last few years, the incidence of therapy-related tumors has increased considerably. This implies a serious problem as they often do not respond to conventional treatments and have a worse evolution than de novo-cases. Therefore, understanding their origin, risk and functioning is key to future diagnoses and treatments. In this article, researchers evaluated if genetic variants in two genes of the p53 pathway (TP53 and MDM2) can be related to therapy-related myeloid neoplasms

Polymorphisms in MDM2 and TP53 genes and risk of developing therapy-related myeloid neoplasms

One of the most severe complications after successful cancer therapy is the development of therapy-related myeloid neoplasms (t-MN). Constitutional genetic variation is likely to impact on t-MN risk. We aimed to evaluate if polymorphisms in the p53 pathway can be useful for predicting t-MN susceptibility. First, an association study revealed that the Pro variant of the TP53 Arg72Pro polymorphism and the G allele of the MDM2 SNP309 were associated with t-MN risk. The Arg variant of TP53 is more efficient at inducing apoptosis, whereas the Pro variant is a more potent inductor of cell cycle arrest and DNA repair. As regards MDM2 SNP309, the G allele is associated with attenuation of the p53 apoptotic response. Second, to evaluate the biological effect of the TP53 polymorphism, we established Jurkat isogenic cell lines expressing p53Arg or p53Pro. Jurkat p53Arg cells presented higher DNA damage and higher apoptotic potential than p53Pro cells, after treatment with chemotherapy agents. Only p53Pro cells presented t(15;17) translocation and del(5q). We suggest that failure to repair DNA lesions in p53Arg cells would lead them to apoptosis, whereas some p53Pro cells, prone to cell cycle arrest and DNA repair, could undergo misrepair, generating chromosomal abnormalities typical of t-MN

The VASCERN PPL working group patient pathway for primary and paediatric lymphoedema.

Lymphoedema is caused by an imbalance between fluid production and transport by the lymphatic system. This imbalance can be either caused by reduced transport capacity of the lymphatic system or too much fluid production and leads to swelling associated with tissue changes (skin thickening, fat deposition). Its main common complication is the increased risk of developing cellulitis/erysipelas in the affected area, which can worsen the lymphatic function and can be the cause of raised morbidity of the patient if not treated correctly/urgently. The term primary lymphoedema covers a group of rare conditions caused by abnormal functioning and/or development of the lymphatic system. It covers a highly heterogeneous group of conditions. An accurate diagnosis of primary lymphoedema is crucial for the implementation of an optimal treatment plan and management, as well as to reduce the risk of worsening. Patient care is diverse across Europe, and national specialised centres and networks are not available everywhere. The European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN) gathers the best expertise in Europe and provide accessible cross-border healthcare to patients with rare vascular diseases. There are six different working groups in VASCERN, which focus on arterial diseases, hereditary haemorrhagic telangiectasia, neurovascular diseases, lymphoedema and vascular anomalies. The working group Paediatric and Primary Lymphedema (PPL WG) gathers and shares knowledge and expertise in the diagnosis and management of adults and children with primary and paediatric lymphoedema. The members of PPL WG have worked together to produce this opinion statement reflecting strategies on how to approach patients with primary and paediatric lymphoedema. The objective of this patient pathway is to improve patient care by reducing the time to diagnosis, define the best management and follow-up strategies and avoid overuse of resources. Therefore, the patient pathway describes the clinical evaluation and investigations that lead to a clinical diagnosis, the genetic testing, differential diagnosis, the management and treatment options and the patient follow up at expert and local centres. Also, the importance of the patient group participation in the PPL WG is discussed

Evaluation of appendicitis risk prediction models in adults with suspected appendicitis

Background Appendicitis is the most common general surgical emergency worldwide, but its diagnosis remains challenging. The aim of this study was to determine whether existing risk prediction models can reliably identify patients presenting to hospital in the UK with acute right iliac fossa (RIF) pain who are at low risk of appendicitis. Methods A systematic search was completed to identify all existing appendicitis risk prediction models. Models were validated using UK data from an international prospective cohort study that captured consecutive patients aged 16–45 years presenting to hospital with acute RIF in March to June 2017. The main outcome was best achievable model specificity (proportion of patients who did not have appendicitis correctly classified as low risk) whilst maintaining a failure rate below 5 per cent (proportion of patients identified as low risk who actually had appendicitis). Results Some 5345 patients across 154 UK hospitals were identified, of which two‐thirds (3613 of 5345, 67·6 per cent) were women. Women were more than twice as likely to undergo surgery with removal of a histologically normal appendix (272 of 964, 28·2 per cent) than men (120 of 993, 12·1 per cent) (relative risk 2·33, 95 per cent c.i. 1·92 to 2·84; P < 0·001). Of 15 validated risk prediction models, the Adult Appendicitis Score performed best (cut‐off score 8 or less, specificity 63·1 per cent, failure rate 3·7 per cent). The Appendicitis Inflammatory Response Score performed best for men (cut‐off score 2 or less, specificity 24·7 per cent, failure rate 2·4 per cent). Conclusion Women in the UK had a disproportionate risk of admission without surgical intervention and had high rates of normal appendicectomy. Risk prediction models to support shared decision‐making by identifying adults in the UK at low risk of appendicitis were identified

Conèixer les variants genètiques individuals per personalitzar el tractament contra la Leucèmia Infantil

La individualització del tractament de la Leucèmia Limfoblàstica Aguda és clau per millorar la supervivència dels pacients amb aquesta malaltia, la qual representa un terç de tots els càncers infantils. En aquest estudi es van analitzar uns gens involucrats en la mort de les cèl·lules canceroses i es va trobar una associació entre la presència d'unes variants genètiques en aquests gens i la supervivència dels pacients. Si aquests resultats es confirmen en una sèrie més àmplia de pacients, es podrien identificar aquells individus amb un alt risc de resistència als agents quimioteràpics basats en la mort cel·lular programada (apoptosi), de manera que podrien ser tractats amb altres teràpies més agressives.La individualización del tratamiento de la Leucemia Linfoblástica Aguda es clave para mejorar la supervivencia de los pacientes con esta enfermedad, la cual representa un tercio de todos los cánceres infantiles. En este estudio se analizaron unos genes involucrados en la muerte de las células cancerosas y se encontró una asociación entre la presencia de unas variantes genéticas en estos genes y la supervivencia de los pacientes. Si estos resultados se confirman en una serie más amplia de pacientes, se podrían identificar aquellos individuos con un alto riesgo de resistencia a los agentes quimioterápicos basados en la muerte celular programada (apoptosis), por lo que podrían ser tratados con otras terapias más agresivas.Individualization of treatment for Acute Lymphoblastic Leukemia is key to improving survival for patients with this disease, which accounts for one third of all childhood cancers. This study analyzed genes involved in the death of cancer cells, and found an association between the presence of genetic variants in these genes and the survival of patients. If these results are confirmed in a broader series of patients, those individuals at high risk for resistance to chemotherapy agents based on programmed cell death (apoptosis) could be identified, so they could be treated with other, more aggressive therapies

Possible implicació dels gens MDM2 i TP53 en el risc a desenvolupar neoplàsies mieloides secundàries

En els últims anys, la incidència de càncers secundaris a la teràpia (desenvolupament d'un altre càncer després de superar el primer) ha augmentat considerablement. Aquest fet suposa un problema greu ja que moltes vegades no responen als tractaments convencionals i tenen una pitjor evolució. Per tant, comprendre'n el seu origen, risc i funcionament és clau per futurs diagnòstics i tractaments. En aquest article, s'ha investigat si les variants genètiques dels gens MDM2 i TP53, implicats en la via p53, poden estar associades amb la susceptibilitat a les neoplàsies mieloides (càncers secundaris més freqüents) relacionades amb la teràpia.En los últimos años, la incidencia de cánceres secundarios a la terapia (desarrollo de otro cáncer tras superar el primero) ha aumentado considerablemente. Este hecho supone un problema grave ya que muchas veces no responden a los tratamientos convencionales y tienen una peor evolución. Por lo tanto, comprender su origen, riesgo y funcionamiento es clave para futuros diagnósticos y tratamientos. En este artículo, se ha investigado si las variantes genéticas de los genes MDM2 y TP53, implicados en la vía p53, pueden estar asociadas con la susceptibilidad a las neoplasias mieloides (cánceres secundarios más frecuentes) relacionadas con la terapia.Over the last few years, the incidence of therapy-related tumors has increased considerably. This implies a serious problem as they often do not respond to conventional treatments and have a worse evolution than de novo-cases. Therefore, understanding their origin, risk and functioning is key to future diagnoses and treatments. In this article, researchers evaluated if genetic variants in two genes of the p53 pathway (TP53 and MDM2) can be related to therapy-related myeloid neoplasms